Nuvectis Pharma to Present at H.C. Wainwright BioConnect Investor Conference - May 16, 2024

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company headquartered in Fort Lee, NJ, announced that its Chairman and Chief Executive Officer, Ron Bentsur, will present at the upcoming H.C. Wainwright 2nd BioConnect Investor Conference. The event will be held at the NASDAQ world headquarters in New York City on May 20th, 2024, at 12:00 PM Eastern Time. During the conference, a fireside chat featuring Mr. Bentsur will offer insights into the company's current projects and future plans.

Nuvectis Pharma, Inc. specializes in developing innovative precision medicines aimed at treating serious conditions in oncology where there is a significant unmet medical need. The company is making strides with two promising clinical-stage drug candidates, NXP800 and NXP900.

NXP800 is an oral small molecule that activates GCN2, a critical regulator in cellular stress response. This drug candidate is currently undergoing a Phase 1b clinical trial focused on treating platinum-resistant, ARID1a-mutated ovarian carcinoma. Additionally, NXP800 is being tested in an Investigator-sponsored trial for cholangiocarcinoma, a type of bile duct cancer. The U.S. Food and Drug Administration (FDA) has granted NXP800 Fast Track Designation for platinum-resistant, ARID1a-mutated ovarian carcinoma and Orphan Drug Designation for the treatment of cholangiocarcinoma. These designations are intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.

The second drug candidate, NXP900, is another oral small molecule but with a different mechanism of action. It inhibits the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 is unique because it blocks both the catalytic and scaffolding functions of the SRC kinase, effectively shutting down the signaling pathway entirely. This drug candidate is currently in a Phase 1a dose escalation study, which aims to determine the appropriate dosage for future clinical trials.

The presence of Nuvectis Pharma at the H.C. Wainwright conference underscores the company's commitment to advancing its pipeline and engaging with the investor community. The fireside chat will provide an opportunity for investors and stakeholders to hear firsthand about the progress and potential of Nuvectis's drug candidates.

In summary, Nuvectis Pharma, Inc. is at the forefront of developing precision medicines for oncology, with two innovative drug candidates, NXP800 and NXP900, currently in clinical trials. The upcoming presentation at the H.C. Wainwright 2nd BioConnect Investor Conference will further highlight the company's endeavors to address significant unmet medical needs in cancer treatment.